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Background: Intermittent pneumatic compression (IPC) improves haemodynamics in peripheral arterial disease
(PAD), but its effects on foot perfusion were scarcely studied. In severe PAD patients we measured the foot
oxygenation changes evoked by a novel intermittent IPC device (GP), haemodynamics and compliance to the
treatment. Reference values were obtained by a sequential foot-calf device (SFC).
Methods: Twenty ischemic limbs (Ankle-Brachial Index = 0.5 ± 0.2) of 12 PAD patients (7 male, age: 74.5 ± 10.8 y)
with an interval of 48 ± 2 hours received a 35 minute treatment in supine position with two IPC devices: i) a
Gradient Pump (GP), which slowly inflates a single thigh special sleeve and ii) an SFC (ArtAssist®, ACI Medical, San
Marcos, CA, USA), which rapidly inflates two foot-calf sleeves. Main outcome measure: changes of oxygenated
haemoglobin at foot (HbO2foot) by continuous near-infrared spectroscopy recording and quantified as area-under-curve
(AUC) for periods of 5 minutes. Other measures: haemodynamics by echo-colour Doppler (time average velocity (TAV)
and blood flow (BF) in the popliteal artery and in the femoral vein), patient compliance by a properly developed form.
Results: All patients completed the treatment with GP, 9 with SFC. HbO2foot during the working phase, considered as
average value of the 5 minutes periods, increased with GP (AUC 458 ± 600 to 1216 ± 280) and decreased with SFC
(AUC 231 ± 946 to −1088 ± 346), significantly for most periods (P < 0.05). The GP treatment was associated to significant
haemodynamic changes from baseline to end of the treatment (TAV = 10.2 ± 3.3 to 13.5 ± 5.5 cm/sec, P = 0.004; BF =
452.0 ± 187.2 to 607.9 ± 237.8 ml/sec, P = 0.0001), not observed with SFC (TAV = 11.2 ± 3.4 to 11.8 ± 4.3 cm/sec; BF =
513.8 ± 203.7 to 505.9 ± 166.5 ml/min, P = n.s.). GP obtained a higher score of patient compliance (P < 0.0001).
Conclusions: A novel IPC thigh device, unlike a traditional SFC device, increased foot oxygenation in severe PAD,
together with favourable haemodynamic response and high compliance to the treatment under the present
experimental conditions.
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Table 1 Characteristics of study subjects
Subjects/legs, n 12/20
Age (y) 74.5 ± 10.8
Sex (M/F) 7/5
BMI 26.7 ± 12.4
PAD II B, legs, n (%) 6 (30%)
PAD III, legs, n (%) 12 (60%)
PAD IV, legs, n (%) 2 (10%)





Risk factors and comorbidites, n (%)





Heart diseases 2 (17%)
End stage renal disease 2 (17%)
Stroke 1 (8%)
Abbreviations: BMI Body Mass Index, PAD Peripheral Arterial Disease (stages are
according to Leriche-Fontaine classification).
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Intermittent pneumatic compression (IPC) devices, used
for prophylaxis and treatment of venous and lymphatic
pathologies [1,2], have become of potential interest for
arterial pathologies. The wide spectrum of haemo-
dynamic effects of IPC on shear stress, vascular tone
and arterial-venous pressure gradient increase [3-7]
make IPC devices effective in treating arterial patholo-
gies at intermediate disease stages [8-13], at severe
stages even in presence of tissue lesions [14-18], or post-
operatively to reduce the risk of bypass graft thrombosis
[19]. However, not always successful effects of these de-
vices on foot perfusion have been also reported [20,21].
IPC devices include a pneumatic impulse generator and
inflatable plastic units surrounding a selected area of the
lower limb (mainly the calf and foot or both). They differ
in terms of the size and seat of the sleeve and in the pat-
terns of compression. Sequential compression devices
are haemodynamically superior [9,22-24].
The optimal IPC device should be comfortable, easy to
use, and effective in a short treatment time to improve
compliance. With this in mind, a novel intermittent
thigh compression device for patients with lower limb is-
chaemia [25], called Gradient Pump (GP), was recently
designed on a different haemodynamic concept and
tested to optimize the therapeutic cycle.
The aim of this study is to describe the acute effects of
this original device on foot perfusion by Near-Infrared
Spectroscopy (NIRS), haemodynamic parameters, and
patient compliance in subjects with severe peripheral ar-
terial disease (PAD). These results were compared with
those obtained on the same patients using a sequential




Twelve patients (M = 7, age = 74.5 ± 10.8 y) including 20
diseased limbs affected by PAD at Fontaine stage IIb-III-
IV (Ankle Brachial Index = 0.5 ± 0.2) were measured
after a preliminary clinical and instrumental screening at
the Vascular Surgery Department. All patients had epi-
sodes of critical limb ischemia (CLI) over the past
2 months, with 9 patients (for a total of 14 legs)
experiencing symptoms in the week prior to the evalu-
ations (Ankle Brachial Index ≤ 0.4 and/or ischemic ul-
cers/skin necrosis). The exclusion criteria were: chronic
venous insufficiency of the leg, recent deep vein
thrombosis (< 6 months), extensive infected ulceration,
and severe congestive heart failure (≥ NYHA 3). All
participants gave their written informed consent. The
study was approved by the ethical committee of Ferrara
(Italy). The characteristics of the participants are reported
in Table 1.Intermittent compression devices
The GP [25] consists of an inflatable sleeve having a
length of 50–80 cm and a width of 13 cm, to be posi-
tioned over the mid thigh with a rigid element inside
(length: 9 cm, width: 10 cm) to selectively improve the
compressive effect on the femoral vein. The inflatable
cuff is connected to a compressor that produces variable
levels of pressure set by a manual regulator. The device
includes a manual electromechanical timer to produce
periodic sequences of pressure and the modification and
control of the working/resting cycles. The GP was set to
deliver an operative cycle of a progressive inflation with
a compression phase lasting 20 seconds and a later
decompression phase lasting 40 seconds (1 cycle/
minute).
The intermittent sequential foot-calf compression de-
vice (SFC) (ArtAssist ACI Medical, LLC San Marcos,
CA, USA), available on the market, consists of a com-
pression sleeve positioned at the foot and at the calf and
supplies a high sequential pressure of 120 mmHg first at
the foot and after 3 seconds at the calf, with 17 seconds
of virtually no pressure (3 cycles/minute).
Treatment
The effects of the GP and SFC were measured in the
same subject in the supine position on two different days
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nated so each treatment was used in sequence, with an
equal number of times as first treatment. Each device
was applied after a 10-minute rest in the supine position.
An intermittent treatment was proposed for GP, based
on 5 minutes of work (device on) followed by 5 minutes
of rest (device off ), for a total of 20 minutes of work and
35 minutes of total treatment at a pressure correspond-
ing to the systolic blood pressure minus 20 mmHg with
a maximum value of 120 mmHg. The SFC was applied
for 2 consecutive hours, considering an average duration
of previously published treatment indications [10,12,3,18].
The difference in device appearance made it impossible to
fully blind the patients. However, the patients did not
know which was under study. The operators were not
blinded to the treatments.
Outcome measures
A schematic description of the study design is shown in
Figure 1.
Foot perfusion measurements by near-infrared spectroscopy
The foot perfusion was measured with a continuous
wave system (Oxymon-MK III, Artinis Medical Systems,
Netherlands) providing measures of changes in oxy
(O2Hb) and deoxyhaemoglobin (HHb) concentrations.
The instrument consists of two channels (two equal-
pulsed light sources, two avalanche photodiode detectors
and ambient light protection) using intensity-modulated
light at a 1 Hz frequency and laser diodes at three wave-
lengths (905, 850 and 770 nm) corresponding to high
absorption of O2Hb and HHb with an auto-sensor oper-
ating at 110–240 V (approximately 40 W). The sum of
the O2Hb and HHb, total haemoglobin (tHb), and the
difference between O2Hb and HHb were calculated. The
sensors were positioned at the dorsum of the foot as
previously performed by other Authors [26-28], crossing
the first intermetatarsal space, marking the position of
probes on the skin using a dermographic pen to ensure
that the same area was studied during both treatments.Figure 1 A schematic representation of the experiment. Legend to Fig
near-infrared spectroscopy; ECD, echo-colour Doppler.The measurements were performed continuously for
5 minutes before the treatment to obtain baseline values
and also during the whole treatment duration. Every five
minutes, a marker was included during the phase of re-
cording to facilitate the NIRS trace analysis.
The semiquantitative data obtained as a function of
time were extracted by the software provided by the
NIRS system manufacturer (Oxysoft 2.47) and were
transferred to an electronic spreadsheet (Microsoft Excel
2007). After normalization to zero, the data were analysed
with statistical software (Medcalc 12.2.1.0, Medcalc-
Software, Mariakerke, Belgium) to determine the area
under the curve (AUC) to quantify the individual varia-
tions in HbO2AUC and tHbAUC, as previously reported [29].
Echo-colour Doppler measurements
The echo-colour Doppler measurements were per-
formed before, after 30 minutes of treatment during an
operative cycle, and at the end of the treatment (device
off ). During the operative cycle, the phase of compres-
sion (C phase), and phase of decompression (D phase)
were evaluated. For the GP only, due to its long dur-
ation, the phase of compression was divided into two
sub-phases: the early (pushing) phase, (Cp phase, 5 sec-
onds), and the phase of full (closing) compression (Cc
phase, 15 seconds). A LogiQ S6 (General Electrics, Fair-
field, CT, USA) was used.
The time average velocity (TAV) and the blood flow
(BF) in the popliteal artery and in the femoral vein at
the inguinal level were assessed. If the popliteal artery
was occluded, haemodynamics were recorded in the
Hunterian or gastrocnemius artery. To insonate vessels
at the same point, the positioning point of the probe was
outlined over the patient skin. All of the assessments
were performed by the same operator using a 7.5 MHz
linear array probe in the longitudinal aspect. Doppler sam-
ple volume was placed in the middle of the lumen, with
the angle of incidence of the ultrasonic beam at 45°-60°
(parallel to the flow direction). TAV was obtained by
marking the flow spectrum on the screen of at least fiveure 1: GP, Gradient Pump Device; SFC, sequential foot-calf device; NIRS,
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the ultrasound machine. To obtain the vessel diameter
measurement, two cursor points were placed on the
lumen edges of the near and far vessel walls, perpendicu-
lar to the vessel position on the screen. The BF value was
automatically calculated from these two measurements.
Patient’s compliance
A form including 10 closed-ended questions was devel-
oped to evaluate the devices in terms of symptoms, side-
effects, satisfaction, ease of use, and tolerance (Table 2).
A dichotomic yes/no response format was used. A score
of 1 or 0 was assigned to each question for a favourable
or unfavourable judgment, respectively. A higher total
score corresponded to increased patient compliance, and
vice versa. Patients were interviewed by the same oper-
ator after each treatment period.
Statistical analysis
The continuous variables are expressed as mean ± stand-
ard deviation. The normal distribution of data was veri-
fied by the Kolmogorov-Smirnov test.
Since the baseline values were taken for a 5-minute
period, the effect on foot perfusion of each device (intra-
comparison analysis) was evaluated by comparing the
AUC values of the NIRS parameters of each subsequent
5-minute treatment period with the 5-minute baseline
value, using the paired Student’s T-test. For each device,
the intra-comparison analysis of the haemodynamic pa-
rameters was performed by comparing the baseline
haemodynamic measurements and those collected at
30 minutes and at the end of the treatment using theTable 2 The questions form used to evaluate patient
compliance with treatments and the scores assigned
Yes No
1) Did the treatment get pain in your leg/foot? 0 1
2) Did you feel worsening of pain in your leg/foot during
the treatment?
0 1
3) Did you need to interrupt the treatment because of pain? 0 1
4) Did you feel relief from pain in your leg/foot during
the treatment?
1 0
5) Did you experience pain in your leg/foot or worsening
of pain after the treatment?
0 1
6) Did you feel discomfort/pain at the site of the sleeve? 0 1
7) Is the device easy to use? 1 0
8) Was the duration of the treatment acceptable? 1 0
9) Would you be willing to continue the treatment at home
for 7 days?
1 0
10) Would you recommend the use of the device to somebody
with your problem?
1 0
Questions 2 and 4 considered the presence of ischemic pain before the treatment.paired Student’s T-test. The compliance form scores
from the two devices were compared by the unpaired
Student’s T-test. A p-value ≤0.05 was considered statisti-
cally significant. Medcalc 12.2.1.0 software program
(Medcalc-Software, Mariakerke, Belgium) was used.
Results
All of the patients completed the GP treatment period.
Three patients discontinued the treatment with SFC be-
cause of pain in the compression sleeve. Two of them
stopped the treatment after 35 minutes, one patient
stopped after 10 minutes. No significant changes in sys-
tolic (SBP) and diastolic (DBP) blood pressure were ob-
served following treatment with the two devices (GP:
baseline SBP = 139 ± 23, DBP = 75 ± 11; end SBP = 143 ±
11; DBP = 75 ± 13; SFC baseline SBP = 140 ± 19, DBP = 74 ±
10; end SBP = 156 ± 24; DBP = 81 ± 9). The average settled
pressure of inflation with GP was 112 ± 12 mmHg.
Foot perfusion
One patient (2 diseased legs) was excluded from the
intra-SFC analysis because the treatment with SFC was
stopped early. Seven 5-minute periods of NIRS traces
were recorded during the 35 minutes of treatment for
both devices (Figure 2).
For the SFC, also the last 5-minute period (8th period,
from 115 to 120 minutes) recorded prior to the end of
the 2-hour treatment was considered for the intra-
comparison analysis, except for 3 patients (4 diseased
legs) who discontinued the treatment. For the GP, the
1st, 3rd, 5th and 7th periods correspond to the intermit-
tent compression phases.
For the GP, a significant higher trend of the NIRS pa-
rameters in respect to baseline for most of the 5-minute
periods was recorded, differently from the SFC that
showed a lower trend in respect to baseline during the
whole treatment (Figure 3). The trend for SFC was not
different following a prolonged treatment, with HbO2AUC
and tHbAUC values between 115–120 minutes slightly
lower than at 30–35 minutes.
The tHbAUC trend for each single leg under study dur-
ing the two treatments showed a more heterogeneous
response during SFC treatment (Figure 4).
Echo-colour Doppler measurements
One patient (2 diseased legs) was excluded from the SFC
analysis because the treatment was stopped early. In a
few patients, due to the involuntary movements of the
leg during the C phase at 30 minutes, it was not possible
to accurately collect the data at the arterial side for both
devices (GP: n = 3 patients/5 legs; SFC: n = 5 patients/7
legs). Missing data were assumed not different from the
D phase. On the contrary all data were correctly regis-
tered at the venous side in all phases.
Figure 2 Monitoring of foot oxygenation changes by NIRS with the two devices in the same subject. Legend to Figure 2: a) GP, Gradient
Pump device; b) SFC, sequential foot-calf device; HbO2, oxygenated haemoglobin; tHb, total haemoglobin.
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GP treatment was followed by a significant increase in
TAV (94% and 53%, respectively) and BF (112% and
62%) after 30 minutes, while in Cc-phase, a slight but
significant decrease in BF was recorded (−15%). Signifi-
cant increases in both parameters were recorded at the
end of the treatment (36% and 44%). At the arterial side,
a significant improvement in TAV and BF was observed
at the end of treatment (66% and 71%) (Table 3).
With the SFC, both parameters collected at the fem-
oral vein at 30 minutes resulted in significant differences
during the C phase as compared to baseline (147%), but
not during the D phase or at the end of the treatment.
As for the arterial side, for both parameters a not signifi-
cant increase was recorded during C phase and D phase
at 30 minutes. No changes were recorded for any param-
eters at the end of the treatment (Table 3).
Compliance
All patients answered to all questions form. The GP
treatment was better tolerated with respect to symptom
relief, side effects, satisfaction, ease of use, and tolerance
(GP = 9.5 ± 0.7 vs SFC = 5.7 ± 1.8, P < 0.0001).
Discussion
The study shows that a novel IPC device, based on a dif-
ferent haemodynamic concept and administered with an
interval protocol, significantly improved the foot perfusion
in the ischemic legs of PAD patients. The same effect was
not observed for a traditional sequential foot-calf device
tested in the same group of patients. Similarly, positivehaemodynamic changes in the veins and arteries of the
legs were observed mainly with the GP device, as well as
more positive feedback in terms of symptom relief and
satisfaction. Previous studies aimed to elucidate the most
effective devices to treat PAD patients, has shown that se-
quential compression devices, particularly the foot-calf de-
vices, were more effective than single compression devices
for the foot or calf [9,22-24]. To our knowledge, only one
study evaluated the efficacy of a thigh IPC device, and this
study promoted the device’s applicability [30]. The novel
thigh device was conceived for patients with impaired foot
perfusion at rest and CLI, therefore the increased oxygen-
ation of the ischemic foot is the therapeutic target. To
evoke a favourable distal haemodynamic effect the prox-
imal inflation at the thigh was preferred in order to create
a cyclic squeezing at the femoral vein and generate a pres-
sure gradient to favour the emptying of the distal veins in
the decompression phase and the drainage of the con-
gested foot. The present study aimed therefore to evaluate
the effects on the microcirculatory unit of the foot as well
on the venous and the arterial flow of GP. In order to bet-
ter evaluate the extent of the haemodynamic response of
the device, the effects of an effective sequential IPC device
were also measured on the same patients. In previous
studies, the foot perfusion was evaluated by laser Doppler
flowmetry and transcutaneous oxygen pressure [7,15,16,21].
In our study the NIRS technique was considered optimal
for this purpose, for its capacity to detect the local changes
of blood flow and the degree of oxygenation below the
sensor. Among the NIRS parameters, HHb has been pre-
viously considered the parameter better reflecting the
Figure 3 HbO2AUC, HHbAUC, and tHbAUC changes during the treatment with the two devices. Legend to Figure 3: GP, Gradient Pump
device; SFC, sequential foot-calf device; HbO2AUC, area under curve of oxyhaemoglobin; HHbAUC, area under curve of deoxyhaemoglobin; tHbAUC,
area under curve of total haemoglobin; P1-8, 5’ periods of measurements during the treatment. Data refer to 12 patients/20 diseased legs for GP
device, and 11 patients/18 diseased legs for SFC device.
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utilization during dynamic exercise, and less influenced by
the changes of blood volume [31,32]. In our study we ana-
lysed all the NIRS parameters measured by the device but
we mainly discuss two of them: HbO2 or the amount of
Hb with oxygen in the tissue under the sensor, to define
the degree of oxygen available in the foot, and tHb or the
total blood volume under the sensor.
During the GP treatment, we observed a favourable in-
crease of total haemoglobin as compared to the baseline,
corresponding to an increase of blood volume below the
sensors for almost all legs (Figure 3), with a concomitant
increase of the oxygenated haemoglobin. Following useof the SFC device, we observed a decreased oxygenation
at foot with a mean reduction in blood flow, even if the
analysis of the single legs (Figure 4) showed and hetero-
geneous response with few legs improving the blood
flow. This effect might be influenced by the phase of
compression of the sleeve at the foot in SFC, as previ-
ously observed [19,20], avoided in GP device by per-
forming a proximal selective compression at thigh, and
by the different degree of compression pressures admin-
istered by the devices. SFC, as most of the devices on
the market, has a rapid inflation and fixed pressure. The
GP, in addition to producing a gradual attainment of the
peak pressure, delivers a customizable inflation pressure
Figure 4 tHbAUC changes for each single leg under study
during the treatment with the two devices. Legend to Figure 4:
a) GP, Gradient Pump device; b) SFC, sequential foot-calf device;
tHbAUC, area under curve of total haemoglobin. The continuous lines
connect tHbAUC values recorded each 5-minute period during the
treatment (P1-7) starting from baseline (P0). Data refer to 12
patients/20 diseased legs for GP device, and 11 patients/18 diseased
legs for SFC device.
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temic systolic pressure. This approach avoids the risk of
transitory arterial occlusion that would potentially create
a further reduction of the inflow and a worsening of the
hypoxic condition. The administration of an intervalled
intermittent pneumatic compression by a manual elec-
tromechanical timer enabling a customization of the
working and resting phase duration, aims to maintain a
balance between oxygen supply and oxygen extraction
considering that for the majority of PAD patients previ-
ously tested, the HbO2 values remain higher than base-
line during the off phase of the therapeutic cycle here
proposed (personal observation). It has been postulated
that one mechanism to explain the changes in arterial
leg inflow with IPC is the action on venous pumps[22,30]. In our study, analysing the different phases of a
single operative cycle at the venous side, we observed
that the two devices work according to different haemo-
dynamic approaches, confirming our original concept.
The SFC increases the venous outflow by a double pro-
pulsive thrust from the bottom, with a strong action
during the compression phase, whereas the GP generates
a pressure gradient from the top exerting weaker and
more gradual compression, with a therapeutic action
during the decompression phase. Our findings, not con-
firming the increased inflow previously assessed by Dop-
pler ultrasound under the same SFC stimulus [10,16,23],
are probably influenced by the different condition of
measurements we used and for this reasons we abstained
from a inter-comparison analysis between the two devices.
Rather than the sitting position, we chose the supine pos-
ition for different reasons. From the haemodynamic side
we excluded the unfavourable action of gravity on the ven-
ous return to favour the venous pump. From the clinical
side we aimed to test the efficacy of GP in any type of pa-
tients including those unable to sit being restricted to bed
(e.g. traumatized, severe brain damaged patients) even
with leg ulcers. The improved perfusion, relevant for pa-
tients with CLI, might in fact represent a crucial factor to
favour the repair of trophic lesions, as anecdotally ob-
served in some of the patients included in our rehabilita-
tion program [33].
The evaluation of patient compliance showed a posi-
tive result for GP, better tolerated overall than the SFC.
We interpret this result along with the lack of pain dur-
ing treatment, the ability to apply the sleeve at the foot
in the presence of ulcers or partial amputation, and the
ease of use. The treatment duration plays a role in the
adherence to the treatment. With the GP we aimed to
limit the treatment to the minimum effective duration,
to our knowledge the shortest of all those proposed in
literature for the different devices.
Limitations
Several limitations affect the present study: low sample
size, subjects with different disease severity, even if they
all experienced pain at rest, measurements taken by op-
erators not blinded to the treatment, and only in the su-
pine position. We are aware that the SFC, an effective
device with favourable haemodynamic effects docu-
mented by echo-colour Doppler measurements, was
tested under not optimal conditions [34]. However, even
the supine position, that we considered useful to evalu-
ate the targeted effect of GP on the ischemic foot, is
considered an acceptable procedure [35]. Data might be
affected by inter-day variability of the haemodynamic
conditions. This variability in baseline measurements re-
peated on the same limbs was not tested, however, for
each subject, data were compared to the baseline values.
Table 3 The hemodynamic parameters measured by echo-colour Doppler with the two devices under study
TAVFV P value BFFV P value TAVPA P value BFPA P value










Baseline 10.2 ± 3.3 452.0 ± 187.2 13.8 ± 6.9 96.8 ± 73.6
CP-30’ 18.6 ± 6.7 <0.0001 799.9 ± 351.2 0.0004 14.1 ± 6.8 n.s. 103.4 ± 92.1 n.s.
Cc-30’ 8.4 ± 3.8 n.s 343.4 ± 209.3 0.03 13.0 ± 7.2 n.s. 93.1 ± 75.3 n.s.
D-30’ 15.1 ± 6.1 0.0006 632.2 ± 291.2 0.01 14.3 ± 16.6 n.s. 127.3 ± 97.5 n.s.
End 13.5 ± 5.5 0.004 607.9 ± 237.8 0.0001 16.6 ± 5.7 0.04 154.5 ± 160.5 0.04
SFC
Baseline 11.2 ± 3.4 513.8 ± 203.7 15.5 ± 7.9 110.4 ± 81.0
C-30’ 25.9 ± 7.9 <0.0001 1139.8 ± 269.5 <0.0001 18.6 ± 9.2 n.s. 137.0 ± 79.0 n.s.
D-30’ 10.7 ± 4.7 n.s. 421.7 ± 139.2 0.05 19.0 ± 9.1 n.s. 136.0 ± 82.1 n.s.
End 11.8 ± 4.3 n.s. 505.9 ± 166.5 n.s. 15.1 ± 6.8 n.s. 110.6 ± 66.3 n.s.
Parameters were measured during the different phases of an operative cycle at baseline, after 30 minutes, and at the end of the treatment.
Abbreviations: GP Gradient Pump device, SFC sequential foot-calf device, TAV Time Averaged Velocity, BF Blood Flow, FV Femoral Vein, PA Popliteal artery.
For GP device: Cp, early (pushing) compression phase, and Cc, full (closing) compression phase; D, Decompression phase. For SFC device: C, Compression phase;
D, Decompression phase.
Data refer to 12 patients/20 diseased legs for GP device and 11 patients/18 diseased legs for SFC device.
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ment was not calculated, and measurements of toe pres-
sure or transcutaneous oximetry (TcPO2), useful to
better define the severity of the disease of the subjects,
was not assessed.
Some limitations may derive from the NIRS technique,
for the limited region evaluated, and the related mea-
surements, that might be affected by the patients’ move-
ment during prolonged treatment. The positioning of
the probes at the dorsum of the foot was previously per-
formed by other authors [26-28], even with moderate re-
liability according to Ubbink and Koopman [27]. We are
also aware that the SFC, an effective device with docu-
mented favourable haemodynamic effects, was tested
under not optimal conditions otherwise useful to evalu-
ate the targeted effect of GP on the ischemic foot.Conclusions
The preliminary data presented show that an IPC device
designed according to a novel compression concept, car-
ried out at individualized pressure with an interval cycle,
induced increased foot perfusion and haemodynamic
changes in patients with advanced PAD who well toler-
ated the treatment. Similar results were not observed
using a traditional SFC device under the present experi-
mental conditions. The data need to be confirmed with
a large number of patients homogenized on the basis of
the severity of disease and acuity of symptoms, and also
considering different experimental conditions as the sit-
ting position. The mechanism of action of the device
needs to be clearly studied. In addition, large-scalerandomized trials in patients with CLI and in popula-
tions with ischemic trophic lesions will allow better
evaluation of the clinical efficacy of the novel device.
Abbreviations
AUC: Area under curve; BF: Blood flow; CLI: Critical limb ischemia; C
phase: Compression phase; Cc phase: Full (closing) compression; Cp
phase: Early (pushing) compression phase; D phase: Decompression phase;
HHb: Deoxyhaemoglobin; GP: Gradient Pump; IPC: Intermittent pneumatic
compression; NIRS: Near-infrared spectroscopy; O2Hb: Oxyhaemoglobin;
PAD: Peripheral arterial disease; SFC: Sequential foot-calf device; TAV: Time
average velocity; tHb: Total haemoglobin.
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